Portal de Periódicos da CAPES

Twice Weekly Fluconazole Prophylaxis for Prevention of Invasive Candida Infection in High-risk Infants of <1000 Grams Birth Weight

2005; Elsevier BV; Volume: 147; Issue: 2 Linguagem: Inglês

10.1016/j.jpeds.2005.03.036

1097-6833

David Kaufman, Robert Boyle, Kevin C. Hazen, James T. Patrie, Melinda Robinson, Leigh B. Grossman,

Pneumonia and Respiratory Infections

Objectives We tested the hypothesis that twice weekly prophylactic dosing of fluconazole prevents invasive candidiasis without promoting resistant Candida species in high-risk, preterm infants. Study design We compared our previous dosing schedule (Group A) to a less frequent dosing schedule of twice a week (Group B) of fluconazole prophylaxis for up to 6 weeks in a prospective, randomized, double-blind clinical trial in preterm infants weighing <1000 grams at birth and with an endotracheal tube and/or central vascular catheter over a 24-month period. Weekly surveillance cultures were obtained on study patients. Results Candida colonization was documented in 5 (12%) of 41 Group A and in 4 (10%) of 40 Group B infants. Candida sepsis developed in two (5%) of Group A and one (3%) of Group B infants (risk difference, −0.02; 95% confidence interval, −0.14-0.10; P = .68). All fungal isolates remained sensitive to fluconazole, and no drug side effects were documented. Conclusions Twice weekly dosing of prophylactic fluconazole can decrease Candida colonization and invasive infection, cost, and patient exposure in high-risk, preterm infants weighing <1000 grams at birth. We speculate that lower and less frequent dosing may delay or prevent the emergence of antifungal resistance. We tested the hypothesis that twice weekly prophylactic dosing of fluconazole prevents invasive candidiasis without promoting resistant Candida species in high-risk, preterm infants. We compared our previous dosing schedule (Group A) to a less frequent dosing schedule of twice a week (Group B) of fluconazole prophylaxis for up to 6 weeks in a prospective, randomized, double-blind clinical trial in preterm infants weighing <1000 grams at birth and with an endotracheal tube and/or central vascular catheter over a 24-month period. Weekly surveillance cultures were obtained on study patients. Candida colonization was documented in 5 (12%) of 41 Group A and in 4 (10%) of 40 Group B infants. Candida sepsis developed in two (5%) of Group A and one (3%) of Group B infants (risk difference, −0.02; 95% confidence interval, −0.14-0.10; P = .68). All fungal isolates remained sensitive to fluconazole, and no drug side effects were documented. Twice weekly dosing of prophylactic fluconazole can decrease Candida colonization and invasive infection, cost, and patient exposure in high-risk, preterm infants weighing <1000 grams at birth. We speculate that lower and less frequent dosing may delay or prevent the emergence of antifungal resistance.